CSBA Comments to Centers for Medicare & Medicaid Services (CMS) on Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026
April 14, 2023
The CSBA Board of Directors endorses BIO’s formal comments on
the Medicare Drug Price Negotiation Program, which are appended to this letter.
BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.
The CSBA Board of Directors endorses BIO’s formal comments on
the Medicare Drug Price Negotiation Program, which are appended to this letter.